Evaluation of the Effect of Alogliptin on Tissue Characteristics of the Carotid Wall: Subanalysis of the SPEAD-A Trial by Irie Yoko et al.
Evaluation of the Effect of Alogliptin on
Tissue Characteristics of the Carotid Wall:
Subanalysis of the SPEAD-A Trial
著者 Irie Yoko, Katakami Naoto, Mita Tomoya,
Takahara Mitsuyoshi, Matsuoka Taka-aki, Gosho








権利 (C) The Author(s) 2018. This article is an
open access publication
This article is distributed under the terms of
the Creative Commons Attribution-NonCommercial
4.0 International License
(http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommercial
use, distribution, and reproduction in any
medium, provided you give appropriate credit
to the original author(s) and the source,
provide a link to the Creative Commons
license, and indicate if changes were made.
URL http://hdl.handle.net/2241/00151225
doi: 10.1007/s13300-018-0367-7
Creative Commons : 表示 - 非営利
http://creativecommons.org/licenses/by-nc/3.0/deed.ja
ORIGINAL RESEARCH
Evaluation of the Effect of Alogliptin on Tissue
Characteristics of the Carotid Wall: Subanalysis
of the SPEAD-A Trial
Yoko Irie . Naoto Katakami . Tomoya Mita . Mitsuyoshi Takahara .
Taka-aki Matsuoka . Masahiko Gosho . Hirotaka Watada . Iichiro Shimomura .
Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Collaborators
Received: November 14, 2017 / Published online: January 12, 2018
 The Author(s) 2018. This article is an open access publication
ABSTRACT
Introduction: Ultrasonic tissue characteriza-
tion of the carotid wall using gray-scale median
(GSM) reflects its composition and low-GSM
plaque is considered to be unstable. The present
study evaluated the effect of alogliptin, a
dipeptidyl peptidase-4 inhibitor, on the longi-
tudinal change in GSM, an index of the tissue
characteristics of the carotid wall, in patients
with type 2 diabetes (T2DM).
Methods: This is a post hoc subanalysis using
data obtained from the SPEAD-A trial, a ran-
domized controlled trial that demonstrated the
beneficial effect of alogliptin treatment on the
progression of carotid intima-media thickness
in patients with T2DM with no past history of
apparent cardiovascular disease. A total of 322
subjects (161 in the alogliptin treatment group
and 161 in the conventional treatment group)
were enrolled. The primary outcome was the
change from baseline in mean GSM-CCA
(common carotid artery) during the 104-week
observation period.
Results: Both alogliptin treatment and con-
ventional treatment significantly increased the
mean GSM-CCA (from 60.7 ± 12.3 to
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65.9 ± 10.1, p\0.001 and 58.8 ± 14.4–65.2 ±
12.2, p\0.001, respectively) and there was no
significant difference in changes in mean GSM-
CCA between the treatment groups (p = 0.95).
Additionally, there were no differences in the
changes in the left and right GSM-CCA between
the groups.
Conclusions: A post hoc subanalysis revealed
an improvement of tissue characteristics in the
carotid arterial wall in both the alogliptin
treatment group and the conventional treat-
ment group during the 104-week treatment
period and that there was no significant differ-
ence between the treatment groups.
Clinical Trial Registration: UMIN000019951.
Keywords: DPP-4 inhibitor; Carotid artery;
Diabetes mellitus; Tissue characteristics;
Carotid ultrasound
INTRODUCTION
Cardiovascular disease (CVD) is the main cause
of death and impairment of quality of life in
patients with diabetes mellitus (DM). Therefore,
prevention and management of cardiovascular
risk are critical in these patients.
It is well known that disruption of vulnerable
atherosclerotic plaque plays a crucial role in the
pathogenesis of CVD events and that plaque
disruption is dependent on the tissue charac-
teristics of the plaque lesion: the lipid content,
the presence of neovascular vessels, inflamma-
tory cells in the atheroma, and the thickness of
the fibrous cap [1–4]. Since diabetes is related to
increased vulnerability to plaque disruption and
higher incidence of clinical CVD [5], early
identification of vulnerable plaque and subse-
quent prompt intervention are important to
reducing the incidence of CVD events in the
management of diabetes.
A recent study indicates that noninvasive
ultrasonic tissue characterization of carotid
plaque using gray-scale median (GSM) reflects
plaque composition and that low-GSM plaque,
which consists mainly of neovascular vessels,
has a high lipid content, and is characterized by
inflammatory infiltration, is considered to be
particularly unstable [6]. Furthermore, the GSM
value in the carotid wall can serve as a predictor
of future CVD events in subjects with and
without diabetes, even after adjustment for
traditional risk factors [7–9].
Dipeptidyl peptidase-4 (DPP-4) inhibitors,
which inhibit the degradation of active incre-
tins including glucagon-like polypeptide-1
(GLP-1) by DPP-4, increase the concentration of
active incretins and thereby enhance their glu-
coregulatory effects. In addition to the antidia-
betic properties mentioned above, these
incretin mimetics potentially have anti-
atherosclerotic properties [10]. First, GLP-1
agonists can significantly decrease body weight
and DPP-4 inhibitors are considered weight
neutral, both of which are advantageous prop-
erties given that weight gain is often seen with
other antidiabetic agents [11, 12]. Second, GLP-
1 acts directly on endothelial cells, vascular
smooth muscle cells, monocytes, macrophages,
and lymphocytes, and GLP-1 and GLP-1 recep-
tor agonists have been shown to inhibit foam
cell formation and atherosclerosis by suppress-
ing inflammation and oxidative stress [13–20].
In addition, several in vitro and in vivo experi-
ments have shown that DPP-4 inhibitors can
also inhibit foam cell formation and
atherosclerosis in both a GLP-1-dependent and
GLP-1-independent manner [21–26]. Vittone
et al. demonstrated that treatment of
apolipoprotein E-deficient mice with a DPP-4
inhibitor reduced plaque inflammation and
increased plaque stability, potentially by GLP-1-
mediated inhibition of chemokine-induced
monocyte migration and macrophage MMP-9
release [26]. Such anti-inflammatory and anti-
atherosclerotic effects of DPP-4 inhibitors have
also been confirmed by studies conducted in
clinical settings [25, 27, 28]. Interestingly,
Balestrieri et al. evaluated the effect of incretin-
based therapies in carotid plaques of asymp-
tomatic patients undergoing carotid
endarterectomy. They found that in compar-
ison with non-diabetic plaques, plaques in
patients with DM had increased inflammation
and oxidative stress along with reduced colla-
gen content. Compared with non-incretin-
treated plaques, incretin therapy-treated pla-
ques presented with higher collagen content,
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and less inflammation and oxidative stress,
indicating a more stable plaque phenotype [25].
We recently reported that treatment with
alogliptin, a DPP-4 inhibitor, attenuated the
progression of carotid intima-media thickness
(IMT) compared with conventional treatment
in patients with type 2 diabetes mellitus (T2DM)
[29]. The aim of the Study of Preventive Effects
of Alogliptin on Diabetic Atherosclerosis
(SPEAD-A), a prospective, randomized, open-
label, multicenter, blinded end point study, was
to evaluate the efficacy of alogliptin in pre-
venting the progression of atherosclerosis in
T2DM patients with no past history of apparent
CVD. The primary outcome was the change in
IMT during the 2-year intervention period. This
trial demonstrated that alogliptin potently
inhibited increase in carotid IMT compared
with conventional treatment and that there was
substantial regression of IMT at the end of the
alogliptin treatment period [29]. Although the
exact mechanism is not well understood at
present, it has been hypothesized that the
regression of carotid IMT induced by alogliptin
treatment could be related to stabilization of
atheromatous lipid-rich lesions via suppression
of inflammation and foam cell formation.
However, little is known about the effect of
alogliptin on the tissue characteristics of
atherosclerotic lesions in the carotid wall.
To address this point, we evaluated the effect
of alogliptin on the longitudinal change in the
GSM value, an index of the ultrasonic tissue
characteristics of the carotid wall, in patients




We performed a post hoc analysis based on data
obtained from the SPEAD-A trial [29]. Although
the study design, inclusion and exclusion cri-
teria, study schedule, and measurements of the
SPEAD-A trial have been described in detail
previously [29], the outline is as follows. Par-
ticipants eligible for the study were those who
had T2DM, were aged 30 years or older at the
time of enrollment, had been treated with
agents other than DPP-4 inhibitors adminis-
tered for 3 months or longer, and whose HbA1c
was below 9.4%. Exclusion criteria were (1) type
1 diabetes mellitus or secondary diabetes, (2)
severe infections before or after surgery or sev-
ere trauma, (3) myocardial infarction, angina
pectoris, cerebral stroke, or cerebral infarction,
(4) moderate or severe renal dysfunction (serum
creatinine: men, C 1.4 mg/dL; women,
C 1.2 mg/dL), (5) severe liver dysfunction (as-
partate aminotransferase C 100 IU/L), (6) mod-
erate or severe heart failure (New York Heart
Association stage III or higher), (7) under treat-
ment with an incretin preparation, such as
other DPP-4 inhibitors, at the start of the study,
(8) receiving insulin treatment, (9) receiving
therapeutic drugs not concomitantly adminis-
trable with incretin preparations with regard to
the National Health Insurance program, such as
DPP-4 inhibitors, at the start of the study, (10)
pregnant, lactating, or possibly pregnant
women or those planning to become pregnant,
(11) medical history of hypersensitivity to
investigational drugs, or (12) judged as ineligi-
ble by clinical investigators.
Japanese T2DM patients with no past history
of apparent CVD who periodically attended the
Outpatient Diabetes Clinics at 11 centers across
Japan were asked to participate in this study and
all patients who agreed to participate were
enrolled in the study. Originally, a total of 341
patients were enrolled and randomly allocated
into either the alogliptin group (n = 172) or the
conventional treatment group (using drugs
other than the DPP-4 inhibitor) (n = 169). After
excluding 19 patients from analyses (they
withdrew from the study and/or objected to the
inclusion of their data in any analysis), 161
subjects in the alogliptin treatment group and
161 in the conventional treatment group were
included in the full analysis set.
The protocol was approved by the institu-
tional review board of each participating insti-
tution in compliance with the Declaration of
Helsinki and current legal regulations in Japan.
Written informed consent was obtained from
all the participants after full explanation of the
study. This study has been registered on the
University Hospital Medical Information
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Network Clinical Trials Registry, which is a non-
profit organization in Japan and meets the
requirements of the International Committee of
Medical Journal Editors (UMIN000007396,
UMIN000019951).
Ultrasound Examination
B-mode ultrasonography of the carotid artery
was performed using an ultrasound machine
with a high-frequency ([7.5 MHz) linear
transducer. In accordance with the guidelines of
the Japan Society of Ultrasonics [30], scanning
of the extracranial common carotid artery
(CCA), the carotid bulb, and the internal carotid
artery in the neck was performed bilaterally in
three different longitudinal projections as well
as transverse projections. The IMT was mea-
sured as the distance between two parallel
echogenic lines corresponding to the blood-in-
tima and media-adventitia interface on the
posterior wall of the artery. The measurements
of mean IMT of the CCA (mean IMT-CCA) were
performed using automated digital edge-detec-
tion software (IntimaScope; MEDIA CROSS,
Tokyo, Japan) [31]. The software system aver-
aged 200 points of IMT values in the segment
2 cm proximal to the dilation of the carotid
bulb. The measurements of maximum IMT of
the CCA (max IMT-CCA) were performed at the
site of the thickest point in the CCA. The
method for determining IMT has been descri-
bed in detail in previous reports [29].
The echogenicity of the arterial wall was
evaluated on the basis of the GSM method in a
gray-scale range of 0–255 (0 as the darkest and
255 as the brightest tone). Adobe Photoshop
software (Adobe Systems, version 7.0, San Jose,
CA, USA) was used for image standardization
and calculation of gray-scale values. In accor-
dance with the previous report, the standard-
ization of the B-mode image was performed
using a curve option, so that the GSM for the
blood ranged from 0 to 5, and for the adventitia
from 185 to 195 [32]. Then, the mean IMT-CCA
area (the segment 2 cm proximal to the dilation
of the carotid bulb) was delineated with a free-
hand tool, and the GSM of the selected area was
read from the entire delineated area. Similarly,
if there was an atherosclerotic plaque lesion
(i.e., focal elevated lesion with max IMT-CCA
[1.0 mm), the GSM of the plaque lesion was
also measured using the same method. In the
event multiple plaque lesions were found in one
individual, the plaque with the greatest thick-
ness was subject to GSM measurement and the
GSM value was used as the subject’s represen-
tative value. To avoid inter-reader variability, all
scans were electronically stored and read in
random order by a single reader (Y.I.) who was
unaware of the clinical characteristics and the
treatment group of the subjects.
Outcome Measures
The primary outcome of this study was the
change of GSM value in the mean IMT-CCA
area (in particular, the arithmetic average of the
right and the left GSM values in one individual)
during the 104-week observation period. In
cases where atherosclerotic plaque lesions were
found, the changes of the GSM value in the
plaques were also evaluated. The definitions of
the GSM measures used in this study are as
follows:
• Right GSM-CCA: the GSM value of the
intima-media complex measured in the
mean IMT-CCA area (the segment 2 cm
proximal to the dilation of the carotid bulb)
of the right common carotid artery.
• Left GSM-CCA: the GSM value of the intima-
media complex measured in the mean IMT-
CCA area (the segment 2 cm proximal to the
dilation of the carotid bulb) of the left
common carotid artery.
• Mean GSM-CCA: the arithmetic average of
the right and left GSM-CCA values. (If either
the right or left GSM-CCA value was not
obtained, the value of the other side was
used as the mean GSM-CCA value.)
• Right GSM-plaque: the GSM value of the
plaque lesion (max IMT-CCA [1.0 mm)
with the greatest thickness measured in the
right common carotid artery.
• Left GSM-plaque: the GSM value of the
plaque lesion (max IMT-CCA [1.0 mm)
with the greatest thickness measured in the
left common carotid artery.
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Statistical Analyses
All values are reported as mean ± SD, median
(range), or actual number of subjects with the
percentage in parentheses.
The primary end point was the change in
GSM of the carotid wall from baseline to
104 weeks. The primary analysis was performed
using the mixed-effects model for repeated
measures (MMRM) including treatment group,
time (week), baseline GSM, and interaction
between treatment group and time with an
unstructured covariance structure to model
within-subject variability. Baseline and follow-
up group comparisons were assessed with the
Student t test or Wilcoxon rank sum test for
continuous variables and Fisher’s exact test for
categorical variables.
To evaluate the associations between change
in the mean GSM-CCA and other clinical
parameters such as age, gender, body mass
index (BMI), HbA1c, serum lipid levels (e.g., TC,
HDL-C, TG), blood pressure, smoking status,
and administration of antidiabetic, antihyper-
tensive, antihyperlipidemic, and antiplatelet
drugs, and mean IMT-CCA, regression analyses
including treatment group as a covariate were
performed.
All statistical tests were two-sided with a 5%
significance level. Analyses were performed
using SAS 9.4 software (SAS Institute Inc., Cary,
NC).
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RESULTS
Baseline Characteristics of Study Subjects
The baseline demographic and clinical charac-
teristics of the 322 study participants have been
previously reported (161 subjects in the alo-
gliptin group and 161 in the conventional
treatment group) [29]. At baseline, there were
no significant differences between the aloglip-
tin group and the conventional treatment
group in terms of the clinical parameters: age
was 64.4 ± 9.8 and 64.8 ± 9.1 (p = 0.72), the
percentage of males was 63% and 61%
(p = 0.82), HbA1c was 7.3 ± 0.8% and
7.2 ± 0.8% (p = 0.54), BMI was 24.6 ± 4.3 and
24.9 ± 3.7 (p = 0.49), the prevalence of hyper-
tension was 56% and 57% (p = 1.00), the
prevalence of dyslipidemia was 53% and 58%
(p = 0.43), and the percentage of statin use was
38% and 46% (p = 0.18), respectively.
Alogliptin treatment had a more potent
glucose-lowering effect than the conventional
treatment (- 0.3 ± 0.7% vs. - 0.1 ± 0.8%,
p = 0.004) without an increase in hypoglycemia
[29]. However, the increase in BMI at 104 weeks
was greater in the alogliptin group than in the
conventional treatment group (0.3 ± 1.9 vs.
- 0.3 ± 1.7 kg/m2, p = 0.003). The increase in
serum VCAM-1 levels at 104 weeks was greater
in the alogliptin group than in the conven-
tional treatment group (20 vs. - 8 ng/mL,
p = 0.030). Regarding other markers of inflam-
mation and endothelial injury such as hs-CRP,
interleukin-6, and ICAM-1, however, there were
no significant differences between the treat-
ment groups in differences in parameters from
baseline to 104 weeks (data not shown).
Effect of Alogliptin on the Carotid Wall
According to the results of the SPEAD-A trial,
reductions in the mean common and the right
and left maximum IMT of the carotid arteries at
104 weeks were significantly greater after alo-
gliptin treatment than after conventional
treatment [- 0.026 (SE 0.009) vs. 0.005 mm (SE
0.009), p = 0.022; - 0.045 (SE 0.018) vs.
0.011 mm (SE 0.017), p = 0.025, and - 0.079 (SE
0.018) vs. - 0.015 mm (SE 0.018), p = 0.013,
respectively] [29].
At baseline, mean GSM-CCA and left GSM-
CCA values were measurable in all the study
subjects but right GSM-CCA values were not
measurable in two subjects in the alogliptin
treatment group. Atherosclerotic plaque lesions
were observed in the right CCA in 61 subjects
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(25 subjects in the alogliptin group and 36 in
the conventional treatment group) and in the
left CCA in 76 subjects (38 subjects in the alo-
gliptin group and 38 in the conventional treat-
ment group). The GSM values of these plaques
were measured. There were no significant dif-
ferences in all the GSM measures (i.e., mean
GSM-CCA, right GSM-CCA, left GSM-CCA,
right GSM-plaque, and left GSM-plaque)
between the two treatment groups at baseline
(Table 1).
Both alogliptin treatment and conventional
treatment significantly increased the mean
GSM-CCA (from 60.7 ± 12.3 to 65.9 ± 10.1,
p\0.001 in the alogliptin treatment group and
58.8 ± 14.4 to 65.2 ± 12.2, p\0.001 in the
conventional treatment group), right GSM-CCA
(from 61.2 ± 13.4 to 65.6 ± 10.9, p\0.001 in
the alogliptin treatment group and from
58.7 ± 15.3 to 64.7 ± 13.8, p\0.001 in the
conventional treatment group), and left GSM-
CCA (from 60.5 ± 14.1 to 66.2 ± 12.9, p\0.001










Baseline 161 60.7 ± 12.3 161 58.8 ± 14.0
52 weeks 153 65.7 ± 11.6** 157 64.2 ± 11.2** 0.73 (- 1.62, 3.07) 0.54
104 weeks 150 65.9 ± 10.1** 154 65.2 ± 12.2** 0.07 (- 2.23, 2.38) 0.95
Right GSM-CCA
Baseline 159 61.2 ± 13.4 161 58.7 ± 15.3
52 weeks 152 65.5 ± 12.3** 156 63.9 ± 11.9** 0.89 (- 1.69, 3.46) 0.50
104 weeks 150 65.6 ± 10.9** 154 64.7 ± 13.8** 0.24 (- 2.36, 2.83) 0.86
Left GSM-CCA
Baseline 161 60.5 ± 14.1 161 58.9 ± 15.5
52 weeks 152 65.9 ± 14.0** 157 64.7 ± 13.3** 0.65 (- 2.21, 3.51) 0.66
104 weeks 150 66.2 ± 12.9** 154 65.7 ± 13.9** 0.04 (- 2.71, 2.80) 0.98
Right GSM-plaque
Baseline 25 66.1 ± 14.9 36 60.9 ± 13.7
52 weeks 23 68.3 ± 13.6 35 61.4 ± 13.2 5.81 (- 1.05, 12.67) 0.10
104 weeks 22 68.1 ± 9.7 34 63.1 ± 11.8 4.54 (- 1.50, 10.58) 0.14
Left GSM-plaque
Baseline 38 66.3 ± 19.0 38 59.7 ± 15.1
52 weeks 35 67.1 ± 14.4 37 67.5 ± 11.6** - 2.68 (- 8.65, 3.29) 0.37
104 weeks 33 70.4 ± 19.4 37 67.0 ± 13.4* 1.03 (- 6.31, 8.36) 0.78
Data are mean ± SD unless otherwise stated. Comparisons of GSMs during treatment with those at baseline were per-
formed with one-sample t test based on a mixed-effects model for repeated measures. Differences in Dchange in GSM from
baseline at 52 and 104 weeks between groups were analyzed with a mixed-effects model for repeated measures. Treatment
group, week, interactions between treatment group and week, and baseline GSM were included as ﬁxed effects
*p\0.05; ** p\0.01
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in the alogliptin treatment group and from
58.9 ± 15.5 to 65.7 ± 13.9, p\0.001 in the
conventional treatment group) during the
104-week observation period. There was also a
significant increase in left GSM-plaque in the
conventional treatment group (from
59.7 ± 15.1 to 67.0 ± 13.4, p = 0.01).
The magnitude of the change in GSM values
during the treatment period between the two
treatment groups was compared using the
MMRM (Table 1). These analyses demonstrated
that both alogliptin treatment and conven-
tional treatment significantly increased all the
GSM measures except for right GSM-plaque (in
the conventional treatment group). However,
there was no significant difference in the
change in GSM measures from baseline at 52
and 104 weeks between the two groups. Fur-
thermore, similar findings were shown even
after adjustment for possible confounding fac-
tors such as age, gender, BMI, HbA1c, serum
lipid levels (e.g., TC, HDL-C, TG), blood pres-
sure, smoking status, and administration of
antidiabetic, antihypertensive, antihyperlipi-
demic, and antiplatelet drugs (data not shown).
Finally, we divided the subjects into the tertiles
according to the level of GSM at baseline, and
investigated the effect of alogliptin on low-GSM
(echolucent) and high-GSM (echorich) plaque
separately (Table 2). The change in right-GSM-
plaque in the first tertile (lowest GSM group)
was significantly greater in the alogliptin group
than in the conventional treatment group [26.4
(SE 4.6) vs. 10.9 (SE 2.9), p = 0.01]. However,
there was no significant difference in the
changes in right GSM-plaque in the second and
third tertiles, and left GSM-plaque in any ter-
tiles, between the two treatment groups.
Regression analyses revealed that gender and
age at baseline (regression coefficient ± SE;
3.93 ± 1.55, p = 0.012 and 0.17 ± 0.08,
p = 0.04, respectively) were positively related to
changes in mean GSM-CCA and diastolic blood
pressure at baseline (- 0.17 ± 0.07, p = 0.01)
was negatively related to changes in mean GSM-
CCA. However, there was no statistically sig-
nificant association between the other clinical
parameters including baseline mean IMT-CCA
and mean GSM-CCA.
We also evaluated the relationship between
the changes in GSM during 104 weeks and those
in IMT/plaque thickness in the same site. The
changes in mean GSM-CCA, right GSM-CCA,
and left GSM-plaque were significantly associ-
ated with those in IMT/plaque thickness in the
same site (r = - 0.14, p = 0.02; r = - 0.13,
p = 0.02; r = - 0.28, p = 0.02, respectively),
while the changes in left GSM-CCA and left
GSM-plaque were not.
DISCUSSION
We previously demonstrated that alogliptin, a
DPP-4 inhibitor, more potently inhibited the
progression of carotid IMT than conventional
treatment in patients with T2DM [29]. How-
ever, few studies have evaluated the effect of
DPP-4 inhibitors on the tissue characteristics of
the arterial wall.
The present study, a post hoc subanalysis
using data obtained from a randomized con-
trolled trial that evaluated the efficacy of alo-
gliptin treatment on the progression of carotid
IMT in patients with T2DM, showed that alo-
gliptin treatment significantly increased the
GSM value, an index of ultrasonic tissue char-
acteristics, of the carotid arterial wall over a
104-week observation period. However, inter-
estingly, conventional treatment also increased
GSM of the carotid arterial wall during this
104-week period and there were no significant
differences in the changes of GSM measures
between the two treatment groups.
Although the precise mechanism of the for-
mation of vulnerable plaque with a lipid-rich
core is unclear, it has been hypothesized that
hypercholesterolemia, oxidative stress, inflam-
mation, and insulin resistance are associated
with its formation [33]. Clinical studies have
also shown that the composition of carotid
plaque is related to serum lipid profiles, BMI,
and inflammation markers. Our previous study
revealed that the presence of echolucent low-
GSM plaques in carotid arteries was related to
serum lipid profiles and BMI [34]. Interestingly,
in the present study, total cholesterol levels at
the 52-, 78-, and 104-week observation points
were significantly decreased from the baseline
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in the conventional treatment group [29]. Sim-
ilarly, total cholesterol levels at 52 and 78 weeks
were significantly decreased from the baseline
in the alogliptin treatment group [29]. There-
fore, in both treatment groups, reduction in
serum total cholesterol levels during the treat-
ment period may have led to an increase in
GSM of the carotid arterial wall.
This post hoc subanalysis of the SPEAD-A
trial showed that the tissue characteristics of the
arterial wall were improved in both treatment
groups, although the original study had clearly
demonstrated that alogliptin treatment more
potently inhibited the progression of carotid
IMT than conventional treatment in patients
with T2DM [29]. In addition, there was a weak
but statistical significant association between
changes in GSM and those in IMT or plaque
thickness, suggesting that the improvement of
tissue characteristics of the carotid wall
Table 2 Effect of alogliptin on the carotid plaque according to the level of baseline GSM
n Mean change (SE)
of alogliptin
treatment group









52 weeks 5 20.6 (5.2)** 14 6.6 (3.1)* 14.1 (1.3, 26.8) 0.03
104 weeks 26.4 (4.6)** 10.9 (2.9)** 15.6 (3.9, 27.2) 0.01
Second tertile
52 weeks 10 0.1 (4.2) 11 - 0.1 (4.0) 0.1 (- 12.1, 12.3) 0.99
104 weeks 0.3 (3.1) - 3.1 (3.0) 3.4 (- 5.6, 12.4) 0.44
Third tertile
52 weeks 8 - 5.2 (4.7) 10 - 8.8 (4.2) 3.6 (- 9.8, 17.0) 0.57
104 weeks - 9.2 (4.2)* - 6.6 (3.5) - 2.6 (- 14.4, 9.2) 0.65
Left GSM-plaque
First tertile
52 weeks 11 18.0 (4.0)** 14 21.2 (3.6)** - 3.2 (- 14.5, 8.0) 0.56
104 weeks 17.1 (4.6)** 19.1 (4.1)** - 2.0 (- 14.7, 10.8) 0.75
Second tertile
52 weeks 11 - 0.4 (3.5) 12 1.5 (3.3) - 1.9 (- 11.9, 8.1) 0.69
104 weeks 0.9 (4.0) 3.5 (3.7) - 2.7 (- 14.0, 8.7) 0.63
Third tertile
52 weeks 13 - 10.6 (4.1)* 11 - 6.4 (4.5) - 4.2 (- 18.0, 9.6) 0.53
104 weeks - 2.1 (5.3) - 7.6 (5.7) 5.5 (- 11.5, 22.4) 0.51
Data are mean (SE) unless otherwise stated. Comparisons of GSMs during treatment with those at baseline were performed
with one-sample t test based on a mixed-effects model for repeated measures. Differences in Dchange in GSM from baseline
at 52 and 104 weeks between groups were analyzed with a mixed-effects model for repeated measures. Treatment group,
week, interactions between treatment group and week, and baseline GSM were included as ﬁxed effects
*p\0.05; ** p\0.01
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contributed to the regression of the carotid wall
thickness. However, the determinants of the
tissue characteristics of the carotid wall and
those of the carotid IMT are not the same.
Although regression of carotid IMT is supposed
to be subsequent to pathological changes such
as reduction of cholesterol accumulation in the
local site, the risk factors for the progression of
carotid IMT are reported to include several
parameters including average HbA1c levels
during the observation period [35]. In our
study, although a reduction in serum total
cholesterol levels, one of the most important
determinants for tissue characteristics of arterial
wall, was observed in both treatment groups,
reduction in HbA1c was observed only in the
alogliptin treatment group [29]. For regression
of carotid IMT, therefore, improvement in
hyperglycemia as well as a reduction in serum
total cholesterol levels may be necessary in
patients with DM. Direct anti-atherosclerotic
effects of alogliptin on vascular cells is another
possible explanation for its beneficial effect on
carotid IMT.
There is also a possibility that the beneficial
effect of alogliptin on the tissue characteristics
of the carotid wall was masked by some con-
founding factors. For example, the improve-
ments in the determinants of plaque
echogenicity such as serum lipid profiles and
BMI were relatively greater in the conventional
treatment group as compared to the alogliptin
treatment group in this study, although
between-group differences did not reach statis-
tical significance. Furthermore, the administra-
tion rate of statins during the treatment period
was also relatively higher in the conventional
treatment group than in the alogliptin treat-
ment group: the percentage of statin users was
38% in the alogliptin treatment group and 46%
in the conventional treatment group (p = 0.18)
at baseline, and 39% and 50% (p = 0.06) at
104 weeks. Since statins have a potent anti-
atherogenic effect and have been reported to
decrease IMT and improve the tissue character-
istics of plaques in the carotid artery [36–38],
such an uncontrolled imbalance in the admin-
istration of statins might have masked the
potential beneficial effect of alogliptin.
There is also a possibility that the beneficial
effect of alogliptin on the carotid wall was
dependent on its characteristics at baseline.
Therefore, we evaluated effect of alogliptin on
low-GSM (echolucent) and high-GSM (echor-
ich) plaque separately. Interestingly, change in
the right GSM-plaque in the first tertile (lowest
GSM group) was significantly greater in the
alogliptin group than in the conventional
treatment group but there was no significant
treatment-group difference in the changes of
right GSM-plaque in the second and third ter-
tiles. Although these findings suggested a pos-
sible beneficial effect of alogliptin on low-GSM
(echolucent) plaque in the right carotid, this
was not the case with the left carotid. This dis-
crepancy could be due to lack of statistical
power rather than bilateral difference, since the
number of the subjects in each subgroup was
very small. To evaluate whether the beneficial
effect of alogliptin on the carotid wall was
dependent on its characteristics at baseline,
another study with larger scale is necessary.
Several limitations of our study should be
discussed. First, the present study is a post hoc
subanalysis using data obtained from the
SPEAD-A trial. Second, the ultrasound settings
for each image were not always standardized.
However, the blood was used as the reference
for black and the adventitia as the reference for
white, and gain settings for measurements
within an individual were similar throughout
the study. Therefore, the impact of gain of
ultrasound beam on the GSM value would be
quite small, if any. Third, although adminis-
tration of antidiabetic, antihyperlipidemic, and
antihypertensive drugs may affect the plaque
components, the baseline medical prescriptions
were not matched completely. In addition, it
was not possible to adjust for the effect of
changes in therapeutic regimen during the
observation period. These points should be
confirmed in further studies. Fourth, relatively
low-risk patients were enrolled in the SPEAD-A
trial: patients with a history of CVD or insulin
therapy were not eligible for inclusion in this
study. Indeed, there were relatively few patients
who had low GSM lesions in the carotid wall.
Although a previous study reported that carotid
GSM values in the range of 30–40 are considered
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to be an adequate cutoff to detect individuals at
high risk for CVD [39, 40], the subjects who had
low GSM lesions (GSM-CCA\40) in their car-
otid walls at baseline represented only 10–20%
of all subjects in this study. This may have led to
the beneficial effects of alogliptin on the tissue
characteristics of the carotid wall being under-
estimated. Finally, the subjects included in this
study were Asian T2DM patients without the
severe obesity that is often observed in non-
Asian T2DM patients. It would thus be prema-
ture to generalize our findings to non-Asian
populations.
CONCLUSIONS
A post hoc subanalysis suggests that the tissue
characteristics of the carotid arterial wall were
improved in both the alogliptin treatment
group and the conventional treatment group
during the 104-week treatment period and that
there was no significant difference between the
treatment groups. Prespecified studies with
large sample size would be necessary to confirm
our findings.
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